Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Silvant Capital Management LLC

Silvant Capital Management LLC trimmed its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 8.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 17,676 shares of the biopharmaceutical company’s stock after selling 1,671 shares during the period. Silvant Capital Management LLC’s holdings in Alnylam Pharmaceuticals were worth $8,060,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Norges Bank acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $662,837,000. Holocene Advisors LP acquired a new stake in Alnylam Pharmaceuticals in the second quarter valued at $194,616,000. Orbis Allan Gray Ltd boosted its stake in Alnylam Pharmaceuticals by 29.8% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock valued at $691,771,000 after acquiring an additional 486,489 shares during the last quarter. Massachusetts Financial Services Co. MA bought a new position in Alnylam Pharmaceuticals during the 3rd quarter valued at $162,577,000. Finally, Vanguard Group Inc. grew its holdings in Alnylam Pharmaceuticals by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock worth $6,185,846,000 after acquiring an additional 268,313 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Trading Down 0.4%

Shares of ALNY stock opened at $322.38 on Wednesday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $495.55. The firm has a market capitalization of $42.75 billion, a PE ratio of 188.53 and a beta of 0.36. The stock has a fifty day moving average of $349.24 and a two-hundred day moving average of $412.24. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The business had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same period last year, the business posted ($0.65) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 84.9% on a year-over-year basis. As a group, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on ALNY shares. Truist Financial dropped their target price on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating for the company in a research report on Thursday, January 8th. Barclays began coverage on Alnylam Pharmaceuticals in a research note on Wednesday, January 28th. They issued an “overweight” rating and a $527.00 price target for the company. Stifel Nicolaus boosted their price objective on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Wells Fargo & Company cut their price objective on Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating on the stock in a research note on Tuesday, January 20th. Finally, Leerink Partners reduced their target price on Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $477.96.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Pushkal Garg sold 2,242 shares of the stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $310.08, for a total value of $695,199.36. Following the completion of the transaction, the executive vice president directly owned 24,848 shares in the company, valued at $7,704,867.84. This trade represents a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Jeffrey V. Poulton sold 2,780 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $362.87, for a total transaction of $1,008,778.60. Following the transaction, the executive vice president owned 57,465 shares in the company, valued at $20,852,324.55. This represents a 4.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 53,923 shares of company stock worth $18,072,087 in the last 90 days. Corporate insiders own 1.20% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.